CERo Therapeutics Holdings
South San Francisco, California, United States · Biotechnology, Health Care, Other
CERo Therapeutics Holdings, Inc. is an innovative immunotherapy company focused on advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy, redirecting patient-derived T cells to eliminate tumors by employing pha
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- South San Francisco, California, United States
- Employees
- 16
- Industries
- Biotechnology, Health Care, Other
- Status
- Public (CERO)
- Website
- cero.bio
- Company page
Recent activity at CERo Therapeutics Holdings
- : SEC 8-K (1.01): On October 6, 2026, CERo Therapeutics Holdings, Inc. entered into a Stock Purchase Agreement with SRX Global Inc. to sell all outstanding capital stock of its subsidiary, CERo Therapeutics, Inc. Upon closing, Holdings will receive shares of SRX valued at $1,000,000, based on a defined formula involving stock price, and will have $8,249,643.77 in obligations under a Consolidated Note forgiven. Additionally, SRX will assume approximately $1,562,000 in specified liabilities and indemnify Holdings against claims related to these liabilities. This significant transaction marks Holdings' exit from ownership of the subsidiary, with a strategic financial restructuring involving debt discharge and adjustments to existing financial instruments.
- : SEC 8-K (1.01): On August 27, 2026, Cero Therapeutics Holdings, Inc. completed a secured financing transaction with SRX Global Inc., where the Company issued a Consolidated Senior Secured Promissory Note with an original issue date of the same date. This transaction consolidates certain outstanding convertible grid promissory notes that were previously issued to SRX. The financing is significant as it helps in managing the company's debt obligations and potentially supports its future operations and growth strategies. No specific financial amounts were detailed regarding the Note in the report.
- : SEC 8-K (1.01): On July 14, 2026, CERo Therapeutics Holdings, Inc. entered into a second amended and restated promissory note with SRX Global Inc. This agreement allows the Company to borrow up to $2,085,200, with $671,600 funded on the same day. The note matures on May 28, 2027, and carries a 10% interest rate, with the option for the Lender to convert the outstanding amount into common stock at certain conditions. This transaction is significant as it provides the Company with additional funds while outlining important conversion options for the lender.
Employee benefit plans
CERo Therapeutics Holdings files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
About CERo Therapeutics Holdings: questions and answers
What does CERo Therapeutics Holdings do?
CERo Therapeutics Holdings, Inc. is an innovative immunotherapy company focused on advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy, redirecting patient-derived T cells to eliminate tumors by employing pha
Where is CERo Therapeutics Holdings headquartered?
CERo Therapeutics Holdings is headquartered in South San Francisco, California, United States.
How many employees does CERo Therapeutics Holdings have?
CERo Therapeutics Holdings has about 16 employees.
What is the latest news on CERo Therapeutics Holdings?
On Oct 07, 2026, SEC 8-K (1.01): On October 6, 2026, CERo Therapeutics Holdings, Inc. entered into a Stock Purchase Agreement with SRX Global Inc. to sell all outstanding capital stock of its subsidiary, CERo Therapeutics, Inc. Upon closing, Holdings will receive shares of SRX valued at $1,000,000, based on a define
Is CERo Therapeutics Holdings a public company?
Yes. CERo Therapeutics Holdings is publicly traded under the ticker CERO.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy